What changed in January 2026
FDA requested removal of suicidal ideation and behavior language from the labels of Saxenda, Wegovy and Zepbound after its review did not identify an increased risk. The review included 91 placebo-controlled trials with 107,910 participants, plus a large Sentinel claims analysis. This updated the agency’s earlier evaluation. When reading an older article, check whether it reports the earlier concern as though it were the current regulatory conclusion.[1]
Why reports and causation are different
An event occurring after a medicine is started is a reason to investigate, but timing alone does not establish that the medicine caused it. A comparator helps ask whether the event occurs more often than it otherwise would. FDA used more than one evidence source to investigate this question. The outcome of that review should not be flipped into the opposite unsupported claim that GLP-1 drugs treat depression or prevent suicide.[1]
A warning change does not dismiss a person’s symptoms
Population-level evidence and an individual’s need for care are different questions. New depression, major changes in mood or thoughts of self-harm still deserve prompt professional attention. NIMH advises seeking immediate help for a suicidal crisis; in the United States, call or text 988, and call 911 for a life-threatening emergency. A reassuring medication headline is not a reason to wait for a routine subscription message when urgent support is needed.[2]
How to read an old safety article
Make a three-column note: publication date, evidence discussed and current regulator conclusion. A story can accurately describe what was uncertain in 2024 and still be incomplete for a decision in 2026. Conversely, a newer date does not prove that a page incorporated the update. Look for a direct reference to the actual review, rather than relying on the year in a title or a general “medically reviewed” label. Our research-reading guide explains how different study designs answer different questions.
Prepare a useful medication conversation
If concerned about a change in mood, note when it began, other changes in health or medicines and how it affects daily life. Share this with a qualified clinician rather than trying to determine causation from an online checklist. Ask who should coordinate follow-up and how to reach appropriate support. The aim is to make the clinical conversation easier, not to use an affiliate article to diagnose a medication reaction.
A practical way to communicate uncertainty
Two statements can both be true: the regulator did not find an increased population-level risk, and a particular person needs help for distressing symptoms. There is no need to choose between acknowledging the evidence and taking the person seriously. When preparing a nonurgent appointment, separate the observation from the explanation: describe what happened and when, then ask the clinician to evaluate possible causes. Avoid changing the observation to fit a preferred medication narrative or assuming an online anecdote settles the cause.
What to ask of a prescribing service
Before enrolling, establish how the service handles mental-health history, symptom reports, referrals and urgent concerns. Ask whether routine messaging is monitored continuously or only during stated hours. Do not infer crisis-care capability from the presence of a chat button. A provider can be convenient for scheduled weight-management care without being the correct route for every urgent medical or mental-health issue. These are service questions to include when choosing a GLP-1 provider.
Continue your research
Sources & scope
Sources checked October 13, 2026. This guide explains published information and consumer research questions; it is not a clinical evaluation.
Prices and terms can change. Confirm your specific offer directly with the provider.